Many healthcare systems offer injection training with diabetes educators or nurses, which can be invaluable for patients new to self-injection or those experiencing persistent injection site issues
Limitations of the therapeutic use of superoxide dismutase Due to the instability, high immunogenicity, low cellular uptake and less in vivo circulation of the half-life of superoxide dismutase, their clinical use as therapeutic agents is very limited
Eligibility criteria for NHS-funded GLP-1 treatment for weight management include: For semaglutide (Wegovy): BMI 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) with at least one weight-related comorbidity For liraglutide (Saxenda): Similar BMI criteria as defined in NICE TA664 Evidence of previous weight management attempts through lifestyle modification Treatment must be initiated within specialist weight management services (Tier 3) Time-limited use as specified in the relevant NICE guidance The referral pathway typically involves: Initial GP consultation: Discuss weight concerns, document BMI and comorbidities, and review previous weight management efforts Tier 2/3 weight management services: Many areas require participation in structured lifestyle programmes before pharmacological intervention Specialist assessment: Referral to specialist weight management services for treatment initiation Ongoing monitoring: Regular review to assess response, tolerability, and continuation criteria Treatment continuation requires achieving the weight loss thresholds specified in the product-specific NICE guidance and SmPCs
Ozempic (semaglutide) is a prescription medication that is approved only in injectable form
Im waiting for my 6 months waiting period to see if I actually have any chances if regrowing any hair or is it a dead non existent follicle
They should offer a thorough consultation before treatment and maintain a clean, clinical environment
